Recent Updates
Recently added Catalysts

LY517717

Phase 2

Total Knee Replacement | Small molecule | Musculoskeletal |Eli Lilly and Company|Last Updated: Mar 31, 2008

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment511

FDA Designations

No designations recorded

Clinical trial landscape

LY517717 · 1 trial · 2 indications

Phase 2 1
NCT00074828New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement SurgeryTotal Knee Replacement
COMPLETED511 Analytics
PHASE2COMPLETED
New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery
Total Knee Replacement
NCT00074828511
Unlock trial analytics

Study Endpoints

Primary Endpoints

Efficacy of LY517717 to enoxaparin in the prevention of VTEs measured by the proportion of patients with VTE event (DVT and/or PE) as confirmed by bilateral venography or on clinical assessment
end of study drug administration

Secondary Endpoints

Safety and tolerability, major and minor bleeding, death due to VTE, effect on QTc duration, AEs and SAEs, hepatobiliary and other safety lab parameters
baseline, daily during therapy, at follow up visit
Pharmacokinetics and pharmacodynamics
predose, daily during therapy
Compare the effect of LY517717 versus enoxaparin measured by DVT, Proximal DVT, Distal DVT and PE
end of study drug administration
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
AEXPERIMENTAL -
BACTIVE_COMPARATOR -

Interventions

NameTypeDescription
LY517717DRUG -
enoxaparinDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites8

Inclusion Criteria: * Are scheduled for total knee or hip replacement surgery (only one side, first time joint replacement) * Are at least 18 years of age and no more than 75 years of age. * Have a body weight more than 50 kg and less than 120 kg. * Sign an approved Eli Lilly and Company informed c...

Countries:AustraliaAustriaBelgiumCzechiaGermanyHungaryItalyPoland
Unlock Eligibility Criteria

Frequently asked questions about LY517717

What is LY517717 used for?

LY517717 is an investigational small molecule being studied for the prevention of blood clots following total knee replacement and total hip replacement surgery. It is being developed for use in the musculoskeletal therapeutic area, specifically for patients undergoing these orthopedic procedures.

Who makes LY517717?

LY517717 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical research to evaluate the drug's safety and efficacy in preventing blood clots after joint replacement surgery.

What phase is LY517717 in?

LY517717 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness. The drug is being studied for the prevention of blood clots following hip or knee replacement surgery.

What clinical trials is LY517717 in?

LY517717 has been studied in one completed clinical trial, identified as NCT00074828. This Phase 2 trial, titled "New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery," enrolled 511 participants across multiple countries including Australia, Austria, Belgium, Czechia, Germany, Hungary, Italy, and Poland.

How does LY517717 work?

LY517717 is a small molecule designed to act as an oral anticoagulant, which means it works to prevent blood clots from forming. The drug is being investigated for its ability to reduce the risk of blood clots in patients undergoing total knee or hip replacement surgery, a common complication following these procedures.